Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Cost Reimbursement

Drugs

Locations

Clinical Specialty

581-600 of 991 trials

Bevacizumab vs. Corticosteroids for Cerebral Radiation Necrosis

We are studying whether bevacizumab is more effective than corticosteroids for treating symptoms of cerebral radiation necrosis in patients with high-grade glioma or brain metastases. The trial also looks at quality of life and other health impacts.

Brain MetastasesHigh-Grade Glioma>2 yearsConfirmation phase (III)≤5 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteNeurologyOncology

Cardiovascular Disease: Low Dose Rivaroxaban in Advanced CKD

We are studying whether a low dose of rivaroxaban can help reduce serious heart-related events in people with advanced chronic kidney disease or on dialysis. This trial compares the medication to a placebo to see if it offers any benefits.

Heart and Kidney Disease>2 yearsConfirmation phase (III)Investigational Medicines Cost ReimbursementCardiologyNephrology

Liver Cancer: Hyperpolarized Pyruvate MRI Study

We are exploring whether a new MRI technique can help detect small liver tumors earlier in people at risk for hepatocellular carcinoma. This may improve early diagnosis and treatment options.

Primary Liver Cancer>2 yearsEfficacy phase (II)≤5 visits No Placebo Investigational Medicines Cost ReimbursementHepatologyInternal Medicine

Chronic Kidney Disease: Ultra-Sensitive MRI Study

We are investigating how advanced MRI can detect metabolic changes in patients with chronic kidney disease and polycystic kidney disease. This research may help improve diagnosis and treatment monitoring.

Autosomal Dominant Polycystic Kidney Disease (ADPKD)Chronic Kidney Disease>2 yearsEfficacy phase (II)≤5 visits No Placebo Investigational Medicines Cost ReimbursementInternal MedicineNephrology

Plaque Psoriasis: TAK-279 Oral Medication

We are studying a new daily oral treatment for people with moderate-to-severe plaque psoriasis. The trial will help us understand its long-term safety and effectiveness.

Plaque Psoriasis>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementDermatology

Plaque Psoriasis: Zasocitinib vs. Deucravacitinib

We are studying whether a new oral medication, zasocitinib, is more effective than deucravacitinib for treating moderate-to-severe plaque psoriasis. The trial will also assess the safety and tolerability of both treatments.

Plaque Psoriasis6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementDermatology

CIDP Treatment: Rituximab Study

We are investigating whether adding Rituximab to IVIg treatment can help people with CIDP achieve long-term remission. This may reduce the need for regular infusions and associated healthcare costs.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)>2 yearsConfirmation phase (III)6-10 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineNeurology

Botox for Inability to Belch

We are studying whether Botox injections into the upper esophageal sphincter can help people who struggle to belch. This trial compares the effects of Botox with a placebo to assess symptom improvement.

Esophageal Disorders>2 yearsMonitoring phase (IV)≤5 visits Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyOtolaryngology

HER2-Positive Gastric Cancer: Rilvegostomig Treatment Study

We are comparing a new treatment combining rilvegostomig with other medications to standard therapies for patients with HER2-positive gastric cancer. The goal is to see if this new approach improves survival and reduces disease progression.

HER2-positive Gastric Cancer>2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

GTX-102 for Children with Angelman Syndrome

We are studying whether GTX-102 can improve cognitive function and other skills in children with deletion-type Angelman Syndrome. The trial also aims to evaluate the safety of this new treatment.

Angelman's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Advanced Solid Tumors: Repotrectinib Study

We are testing a new treatment called repotrectinib for patients with advanced solid tumors that have specific genetic changes. The study aims to evaluate its safety and effectiveness in improving tumor response.

Advanced Solid Tumors3-6 monthsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementOncology

Primary Aldosteronism: New Imaging Technique Study

We are comparing a new PET/CT imaging method with a standard test to see which better identifies adrenal tumors in patients with primary aldosteronism. This may help improve treatment for hypertension linked to this condition.

Primary Hyperaldosteronism1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteCardiologyEndocrinology

X-Linked Hypohidrotic Ectodermal Dysplasia: ER004 Treatment

We are studying a new prenatal treatment for male infants with X-linked hypohidrotic ectodermal dysplasia to see if it improves sweating ability and dental health. The trial also examines the safety of this treatment for both the infants and their mothers.

X-linked Hypohidrotic Ectodermal Dysplasia≤3 monthsEfficacy phase (II)≤5 visits No Placebo Investigational Medicines Cost Reimbursement Partially RemoteDermatologyInternal MedicinePediatrics

Crohn's Disease: SAR441566 Treatment Study

We are investigating how different doses of SAR441566 affect symptoms and health in adults with moderate to severe Crohn's disease. This study aims to find out if the medication can help improve patients' quality of life and overall condition.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Sickle Cell Disease and β-Thalassemia: CTX001 Treatment Study

We are studying the long-term safety and effectiveness of a new CRISPR-based treatment for patients with β-thalassemia or severe sickle cell disease. This research aims to understand how well the treatment works over time.

Sickle Cell DiseaseTransfusion Dependent ThalassemiaConfirmation phase (III)No Placebo Standard Medicines Cost Reimbursement Partially RemoteHematology

Systemic Juvenile Idiopathic Arthritis: Sarilumab Study

We are testing the medication sarilumab in children and adolescents with systemic juvenile idiopathic arthritis to find the best dose and understand its effects and safety.

Systemic Juvenile Idiopathic Arthritis (sJIA)3-6 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemotePediatricsRheumatology

Relapsing Multiple Sclerosis: Obexelimab Study

We are testing a new medication, Obexelimab, to see if it helps prevent new brain lesions in people with relapsing multiple sclerosis. The study will also assess the safety of this treatment compared to a placebo.

Relapsing-Remitting Multiple Sclerosis1-2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementInternal MedicineNeurology

INZ-701 for ENPP1 and ABCC6 Deficiency

We are studying the long-term safety of INZ-701 in patients with ENPP1 and ABCC6 deficiencies. This trial will help us understand how the drug works over time and its effects on certain blood markers.

Pseudoxanthoma ElasticumEctonucleotide Pyrophosphatase/Phosphodiesterase 1 DeficiencyGeneralized Arterial Calcification of InfancyEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteDermatologyInternal Medicine

Non-Transfusion-Dependent Thalassemia: Mitapivat Study

We are studying whether Mitapivat can improve anemia in people with non-transfusion-dependent alpha or beta thalassemia. This trial compares the medication to a placebo to evaluate its effects.

Non-Transfusion Dependent Thalassemia3-6 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematology

Advanced Solid Tumors: VERT-002 Study

We are studying a new anticancer drug, VERT-002, for patients with advanced solid tumors, including lung cancer with MET alterations. The trial aims to assess its safety and how well it may work.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Search Clinical Trials in the European Union